- Home
- ENGN vs ACIU Comparison
ENGN vs ACIU Comparison
Compare ENGN & ACIU Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ENGN
- ACIU
- Stock Information
- Founded
- ENGN 1999
- ACIU 2003
- Country
- ENGN Canada
- ACIU Switzerland
- Employees
- ENGN N/A
- ACIU N/A
- Industry
- ENGN
- ACIU Biotechnology: Pharmaceutical Preparations
- Sector
- ENGN
- ACIU Health Care
- Exchange
- ENGN Nasdaq
- ACIU Nasdaq
- Market Cap
- ENGN 297.7M
- ACIU 247.4M
- IPO Year
- ENGN N/A
- ACIU 2016
- Fundamental
- Price
- ENGN $4.00
- ACIU $1.48
- Analyst Decision
- ENGN Buy
- ACIU Strong Buy
- Analyst Count
- ENGN 9
- ACIU 2
- Target Price
- ENGN $25.22
- ACIU $12.00
- AVG Volume (30 Days)
- ENGN 46.1K
- ACIU 194.4K
- Earning Date
- ENGN 06-13-2025
- ACIU 05-12-2025
- Dividend Yield
- ENGN N/A
- ACIU N/A
- EPS Growth
- ENGN N/A
- ACIU N/A
- EPS
- ENGN N/A
- ACIU N/A
- Revenue
- ENGN N/A
- ACIU $30,136,397.00
- Revenue This Year
- ENGN N/A
- ACIU N/A
- Revenue Next Year
- ENGN N/A
- ACIU $676.94
- P/E Ratio
- ENGN N/A
- ACIU N/A
- Revenue Growth
- ENGN N/A
- ACIU 84.51
- 52 Week Low
- ENGN $3.50
- ACIU $1.43
- 52 Week High
- ENGN $16.62
- ACIU $4.98
- Technical
- Relative Strength Index (RSI)
- ENGN 33.30
- ACIU 24.24
- Support Level
- ENGN $3.77
- ACIU $1.48
- Resistance Level
- ENGN $4.19
- ACIU $1.62
- Average True Range (ATR)
- ENGN 0.40
- ACIU 0.12
- MACD
- ENGN 0.01
- ACIU -0.00
- Stochastic Oscillator
- ENGN 38.46
- ACIU 9.43
About ENGN enGene Holdings Inc.
enGene Holdings Inc is a clinical-stage biotechnology company focused on developing gene therapies to improve the lives of patients. The Company is developing non-viral gene therapies based on its novel and proprietary dually derived chitosan, or DDX, gene delivery platform, which allows localized delivery of multiple gene cargos directly to mucosal tissues and other organs.
About ACIU AC Immune SA
AC Immune SA is a clinical-stage biopharmaceutical company that focuses on neurodegenerative diseases. The company uses its proprietary technology platforms to discover, design, and develop novel proprietary small molecules, antibodies, and vaccines for the prevention, diagnosis, and treatment of neurodegenerative diseases associated with protein misfolding. The Company has one segment. The Company currently focuses most of its resources on discovering and developing therapeutic and diagnostic products targeting misfolded proteins. The company's pipeline consists of ACI-24.060, Crenezumab, ACI-35.030, Semorinemab, ACI-7104.056, and others.